SecBot SecBot
8-K ·Filed Jul 30, 2026

KROS

Keros Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001664710-26-000043
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The milestone payment and Phase 3 initiation de-risk the elritercept program and provide a near-term capital return catalyst via the 25% distribution. Monitor for timing of payment receipt and any subsequent updates on trial enrollment or additional milestones from Takeda.

DirectionBullish
Confidencehigh
Horizonweeks

elritercept

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3 (MDS); Phase 3 planned (myelofibrosis)
Time to market
Unknown — several years: the Phase 3 ELRiSE MDS trial (elritercept vs epoetin alfa in low-risk MDS) only began dosing patients in July 2026, and the myelofibrosis Phase 3 is planned but not yet underway; no regulatory filing or PDUFA exists.
Next catalyst
None dated

What to watchWatch KROS's Q2 2026 earnings (before market open, Aug 4, 2026) and any timing update on the 25% shareholder distribution of the $20M Takeda milestone. The next real value inflection, a Phase 3 readout, is years out, so near-term moves will be driven by Takeda milestones, financing/dilution news (no approved product; cash burn continuing), and execution on the ELRiSE MDS enrollment.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.07
T+0 close · Jul 30, 2026 · via day close
Latest settled
+12.51%
T+60 · $11.33
Vs SPY
+10.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $10.07entry
  2. T+1 · 4mo ago +0.40%α −1.03% · $10.11
  3. T+5 · 3mo ago +10.72%α +7.21% · $11.15
  4. T+20 · 3mo ago +9.53%α +6.55% · $11.03
  5. T+60 · 22d ago +12.51%α +10.06% · $11.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this milestone to stockholders, providing a tangible near-term capital return catalyst.

Key Facts

  • $20 million development milestone payment from Takeda triggered by first patient dosed in Phase 3 ELRiSE MDS trial
  • Phase 3 trial (ELRiSE MDS) is a multicenter, open-label, randomized study comparing elritercept vs epoetin alfa in low-risk MDS
  • Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders
  • Under the global license agreement (effective Jan 16, 2025), Keros received $200M upfront in Feb 2025 and is eligible for up to $1.1B+ in milestones plus tiered royalties

Financial Impact

$20 million milestone payment (~10% of $197M market cap); 25% of net proceeds to be distributed to shareholders

cashshareholder distributions

Risk Factors

  • Clinical trial risk: Phase 3 ELRiSE MDS may fail to meet endpoints
  • Dependence on Takeda partnership for development and commercialization
  • No approved products; pre-revenue stage with ongoing operating losses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000043
Exhibit: exhibit99173026pr.htm0001664710-26-000043
Document: 0001664710-26-000043-index-headers.html0001664710-26-000043
Document: 0001664710-26-000043-index.html0001664710-26-000043
Document: 0001664710-26-000043.txt0001664710-26-000043

Track record

27 reports on KROS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +7.84% at T+20 after the Mar 9, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026